Sun Pharma Receives 'AAA/Stable' Ratings for INR 15,000 Crore NCD Issue
Sun Pharmaceutical Industries Ltd · Others (Uncategorized) · 13 Oct 2026, 11:23 pm
Sun Pharma Receives 'AAA/Stable' Ratings for INR 15,000 Crore NCD Issue On 13th Oct'26, CRISIL and ICRA assigned 'AAA/Stable' ratings to Sun Pharma's proposed INR 15,000 crore NCD programme and reaffirmed 'A1+' on its INR 4,000 crore CP facility. The ratings factor in the proposed USD 11.75 billion acquisition of Organon & Co. Net debt to EBITDA is projected to rise temporarily to 1.5–2.0x in FY28 before deleveraging. In Q1 FY27, operating income rose ~10% YoY to INR 15,300 crore with a 29% operating margin, backed by strong growth in India and innovative medicines.
Original exchange filing (PDF)
More announcements from Sun Pharmaceutical Industries Ltd
- Intimation of Schedule of Analyst/Institutional Investor Meeting · 05 Nov 2026
- Q2FY27 Earnings Call Transcript · 05 Nov 2026
- Clarification regarding news report relating to the Company''s Assam facility · 03 Nov 2026
- The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on November 2, 2026, with reference to news appeared in https://www.thehindu.com/ dated October 30, 2026 quoting .... · 02 Nov 2026
- Completion and results of postal ballot dated 01 October 2026 · 01 Nov 2026
- Q2FY27- Investor Call Audio Recording · 31 Oct 2026
- Board Meeting Outcome - Conclusion · 30 Oct 2026
- Unaudited Financial Results for the quarter and half year ended 30 September 2026 · 30 Oct 2026
